MOLECULAR SUBTYPING, PROGNOSIS AND TREATMENT OF PROSTATE CANCER
The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.
1 . A method comprising: providing a biological sample from a prostate cancer subject; detecting the presence or expression level of at least one or more targets selected from Table 1, Table 2, Table 6, Table 7, Table 15 or SEQ ID NOs: 1-3348; and administering a treatment to the subject, wherein the treatment is selected from the group consisting of surgery, chemotherapy, radiation therapy, immunotherapy/biological therapy, hormonal therapy, and photodynamic therapy.
2 . The method of claim 1 , wherein the alteration in the expression level of said target is reduced expression of said target.
3 . The method of claim 1 , wherein the alteration in the expression level of said target is increased expression of said target.
4 . The method of claim 1 , wherein the level of expression of said target is determined by using a method selected from the group consisting of in situ hybridization, a PCR-based method, an array-based method, an immunohistochemical method, an RNA assay method and an immunoassay method.
5 . The method of claim 1 , wherein said reagent is selected from the group consisting of a nucleic acid probe, one or more nucleic acid primers, and an antibody.
6 . The method of claim 1 , wherein the target comprises a nucleic acid sequence.
7 . A method comprising:
(a) providing a biological sample from a subject with prostate cancer;
(b) detecting the presence or expression level in the biological sample for a plurality of targets, wherein the plurality of targets comprises one or more targets selected from Table 1, Table 2, Table 6, Table 7, Table 15 or SEQ ID NOs: 1-3348;
(c) subtyping the prostate cancer in the subject based on the presence or expression levels of the plurality of targets; and
(d) administering a treatment to the subject, wherein the treatment is selected from the group consisting of surgery, chemotherapy, radiation therapy, immunotherapy/biological therapy, hormonal therapy, and photodynamic therapy.
8 . The method of claim 7 , wherein the expression level of said target is reduced expression of said target.
9 . The method of claim 7 , wherein the expression level of said target is increased expression of said target.
10 . The method of claim 7 , wherein the level of expression of said target is determined by using a method selected from the group consisting of in situ hybridization, a PCR-based method, an array-based method, an immunohistochemical method, an RNA assay method and an immunoassay method.
11 . The method of claim 7 , wherein said reagent is selected from the group consisting of a nucleic acid probe, one or more nucleic acid primers, and an antibody.
12 . The method of claim 7 , wherein the target comprises a nucleic acid sequence.
13 . The method of claim 7 , wherein the prostate cancer subtype is selected from the group consisting of ERG+. ETS+, SPINK1+, and Triple-Negative.
14 . A system for analyzing a cancer, comprising:
(a) A probe set comprising a plurality of target sequences, wherein
(i) the plurality of target sequences hybridizes to one or more targets selected from Table 1, Table 2, Table 6, Table 7, Table 15 or SEQ ID NOs: 1-3348; or
(ii) the plurality of target sequences comprises one or more targets selected from Table 1, Table 2, Table 6, Table 7, Table 15 or SEQ ID NOs: 1-3348; and
(b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target hybridized to the probe in a sample from a subject suffering from prostate cancer.
15 . The system of claim 14 , further comprising a label that specifically binds to the target, the probe, or a combination thereof.
16 . A method of treating a subject with prostate cancer, comprising: providing a biological sample comprising prostate cancer cells from the subject; determining the level of expression or amplification of at least one or more targets selected from Table 1, Table 2, Table 6, Table 7, or Table 15 using at least one reagent that specifically binds to said targets; subtyping the prostate cancer based on the level of expression or amplification of the at least one or more targets; and prescribing a treatment regimen based on the prostate cancer subtype.
17 . The method of claim 16 , wherein the prostate cancer subtype is selected from the group consisting of ERG+. ETS+, SPINK1+, and Triple-Negative.
18 . A kit for analyzing a prostate cancer, comprising:
(a) a probe set comprising a plurality of target sequences, wherein the plurality of target sequences comprises at least one target sequence listed in Table 1, Table 2, Table 6, Table 7, Table 15 or SEQ ID NOs: 1-3348; and
(b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target sequences in a sample.
19 . The kit of claim 18 , further comprising a computer model or algorithm for correlating the expression level or expression profile with disease state or outcome.
20 . The kit of claim 18 , further comprising a computer model or algorithm for designating a treatment modality for the individual.
21 . The kit of claim 18 , further comprising a computer model or algorithm for normalizing expression level or expression profile of the target sequences.